“Reports from Israel that Pfizer may only be about 64% effective against mild cases of Delta variant, but still strong against severe disease”
“Still something like 93% effective against severe illness, yes?”
I think that is what was just reported in Israel.
On another post, someone posted a paper from “Public Health England” (Technical briefing 17
25 June 2021), https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdf
On page 39, they indicate that the vaccine (I believe they are talking about Pfizer BioNTech, but did not verify), was less effective against Delta for symptomatic Disease (79%, vs 89% against Alpha, for fully vaccinated), but was actually MORE effective against hospitalization from Delta (96%, vs. 93% against Alpha, fully vaccinated).
On a different topic, it also notes that C.37 (Lambda), the Peruvian variant, is now on their radar screen as a Variant Under Investigation.
Funny enough, Sinopharm (Chinese vaccine maker) is under investigation in Peru for allegations they bribed public officials to get their vaccine ordered for the country.
All in all, Peru has had continued outbreaks of COVID-19 because they (like much of the rest of Latin America) relied on the Chinese vaccines from CanSino, Sinovac, and Sinopharm, and all of the Chinese vaccines are absolute garbage. You know, like everything else made in China. And because those cheap idiots used those garbage Chinese vaccines, more people got infected, and one of them served as the incubator for this new variant that’s looking like it could be another problem.
Hopefully Pfizer and Moderna get their BLA soon so they can make variant-specific shots available to the public via BLA addendums. I would gladly get one that covers the India, UK, South Africa, and Peru variants. One specifically formulated against those variants should maintain extremely high efficacy. This is the whole promise of the mRNA platform: rapid development and redevelopment that keeps up with mutations.